This year marks the 40th anniversary of a landmark paper describing the discovery of tumour necrosis factor (TNF), a pivotal cell-signalling protein in inflammatory disease known as a cytokine (E. A. Carswell et al. Proc. Natl Acad. Sci. USA 72, 3666–3670; 1975). More than 122,000 publications on TNF followed — including reports that led to an important drug for treating arthritis, etanercept.
TNF's eponymous anti-cancer effects were unwittingly exploited by William Coley and colleagues as long ago as the end of the nineteenth century, after the likely induction of TNF by a mix of bacterial toxins (see B. Wiemann and C. O. Starnes Pharmacol. Ther. 64, 529–564; 1994).
And many centuries earlier, in 1322, a Parisian midwife called Jacoba Felicie successfully burned the tissue around tumours to make them regress. We now know that burns cause inflammation, which activates TNF. As a woman, she was not permitted to qualify as a doctor, so she was put on trial for practising medicine and banished from Paris.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Libert, C. TNF trailblazers five centuries apart. Nature 523, 158 (2015). https://doi.org/10.1038/523158e
Published:
Issue Date:
DOI: https://doi.org/10.1038/523158e
This article is cited by
-
TNF-α contributes to sarcopenia through caspase-8/caspase-3/GSDME-mediated pyroptosis
Cell Death Discovery (2023)
-
Metabolic Messengers: tumour necrosis factor
Nature Metabolism (2021)
-
Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research
Mammalian Genome (2018)